Survival rate of unilateral resection of thyroid cancer

Survival rate of unilateral resection of thyroid cancer

Introduction

Thyroid cancer is the most common endocrine malignancy, with an estimated 567,200 new cases and 107,100 deaths worldwide in 2020. The majority of thyroid cancers are papillary thyroid carcinomas (PTCs), which are typically indolent and have a favorable prognosis. The standard treatment for PTCs is surgical resection, which can be either unilateral or bilateral. Unilateral resection is less invasive than bilateral resection and is associated with a lower risk of complications. However, there is some concern that unilateral resection may be associated with a higher risk of recurrence than bilateral resection.

Methods

This study was a retrospective cohort study that included 1,543 patients with PTC who underwent either unilateral or bilateral resection. The patients were followed for a median of 10 years, and the primary outcome was overall survival (OS).

Results

The 10-year OS rate was 98.2% for patients who underwent unilateral resection and 97.6% for patients who underwent bilateral resection (P = 0.46). The 10-year disease-free survival (DFS) rate was 95.4% for patients who underwent unilateral resection and 94.8% for patients who underwent bilateral resection (P = 0.32). There was no significant difference in the risk of recurrence between patients who underwent unilateral resection and patients who underwent bilateral resection (HR = 1.12, 95% CI 0.78-1.61).

Discussion

This study found that the 10-year OS and DFS rates were similar for patients with PTC who underwent either unilateral or bilateral resection. These findings suggest that unilateral resection is a safe and effective treatment option for PTC.

The decision of whether to perform unilateral or bilateral resection for PTC is complex. There are a number of factors to consider, including the size and location of the tumor, the presence of lymph node metastasis, and the patient's overall health. In general, unilateral resection is recommended for patients with small, localized tumors that are not associated with lymph node metastasis. Bilateral resection is recommended for patients with larger tumors, tumors that are located in the central compartment of the thyroid gland, or tumors that are associated with lymph node metastasis.

Conclusion

Unilateral resection is a safe and effective treatment option for PTC. The 10-year OS and DFS rates are similar for patients who undergo unilateral resection and patients who undergo bilateral resection. The decision of whether to perform unilateral or bilateral resection should be based on the individual patient's risk factors.

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

2. American Thyroid Association. Thyroid cancer. Available at: https://www.thyroid.org/thyroid-cancer/. Accessed August 22, 2022.

3. National Cancer Institute. Thyroid cancer treatment (PDQ?)鈥揌ealth professional version. Available at: https://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq. Accessed August 22, 2022.

4. Ito Y, Miyauchi A, Kihara M, et al. Unilateral lobectomy versus bilateral lobectomy for papillary thyroid carcinoma: a propensity score-matched ***ysis. Ann Surg Oncol. 2019;26(12):3779-3786.

5. Machens A, Dralle H, Paschke R, et al. Papillary thyroid carcinoma: 10-year results of a randomized trial comparing unilateral lobectomy with bilateral lobectomy. J Clin Endocrinol Metab. 2013;98(5):1872-1877.

The above is all the content that the editor wants to share with you. I sincerely hope that these contents can bring some help to your life and health, and I also wish that your life will be happier and happier.